SASilvano Adami

Silvano Adami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Silvano Adami has a total of 266 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CD14++ CD16− monocytes are the main source of 11β-HSD type 1 after IL-4 stimulation

    by Vidya Kunnathully, Macarena Gomez-Lira, Giulio Bassi, Fabio Poli, Elisa Zoratti, Valentina La Verde, Luca Idolazzi, Davide Gatti, Ombretta Viapiana, Silvano Adami, et al.


  • Bone metabolism in patients with anorexia nervosa and amenorrhea

    by Davide Gatti, Luca Idolazzi, Ghoch Marwan el, Ombretta Viapiana, Simona Calugi, Maurizio Rossini, Cristian Caimmi, Vania Braga, Giorgio Radetti, Silvano Adami, et al.

    Context: Anorexia nervosa (AN) occurs predominantly in females, most frequently during adolescence and it is generally associated with amenorrhoea. AN increases the risk for impaired bone health and for low bone mineral density (BMD) by a mechanism which has not been yet well defined. Objective: The study purpose was to further characterize bone metabolism in AN with amenorrhoea, and so with oestrogen deficiency Design: AN patients were compared with healthy females matched for age and with postmenopausal women as a model for oestrogen deficiency. Study popultion: The study population included 81 females with AN: 48 young adults and 33 adolescents. All had amenorrhoea for at least 6 months and none of them had serum 25 OH vitamin D lower than 20 ng/ml. The control groups included age matched healthy young ladies (n=20), 17 healthy adolescents and 21 postmenopausal women. Methods: We studied bone turnover markers, intact parathyroid hormone, 25 hydroxy-vitamin D, Sclerostin (SOST) and Dickkopf-related protein 1. Results: AN participants had higher C-terminal telopeptide of type I collagen (CTX) levels than both control groups. AN adolescents had CTX higher than AN young adults. In postmenopausal women intact N-propeptide of type I collagen was higher as compared with in each other group. In AN groups Dickkopf-related protein 1 was significantly lower than the two control groups. No differences were found in sclerostin except in adolescents. In AN adolescents DXA BMD at femoral sites were higher than in AN young adults and it was found positively correlated with body weight (PP<0,01). Conclusion: Our data suggest that in AN women with amenorrhoea bone resorption is as elevated as in postmenopausal women but bone formation is relatively depressed. The consequent remodelling uncoupling is considerably more severe than that occurring after menopause.


  • Open Access

    Real World Data use and Applications in the Integrated Management of Rheumatic Disease

    by Patrizia Berto, Silvano Adami, Costantino Botsios, Valentina Fantelli, Anna Maria Grion, Francesca Ometto, Leonardo Punzi, Chiara Roni, Giovanna Scroccaro

    Use of real world data is spreading at increasing pace in response to the growing need of ensuring effectiveness and appropriateness in the delivery of health and medical care. Data from clinical trials are essential to define efficacy and safety of medical therapies in experimental conditions, while real world data assume greater relevance when one considers the differences between study populations of clinical trials and people who take the same drug in real life conditions, and the changes that happen over time with the acquisition of new evidence on drugs and treatments. Rheumatoid arthritis is a chronic disease with significant social (direct and indirect) costs that today can be medically managed ensuring both effectiveness and appropriateness. Real world data can contribute significantly to the efficient management of this disease as demonstrated by outstanding examples from Italian registries and databases.

  • Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros

    by Maurizio Rossini, Giovanni Orsolini, Ombretta Viapiana, Silvano Adami, Davide Gatti

    In glucocorticoid-induced osteoporosis (GIO), both bone formation and resorption are altered, however, with a relative prevalence of resorption, consistent with the positive results that have been reported with bisphosphonate treatment. Many studies have investigated the effect of bisphosphonates (BPs), a widely used class of anti-resorptive drugs, showing a positive effect on bone mineral density and fracture risk. Also in case of postmenopausal osteoporosis, the safety and cost-effectiveness profile of BPs in GIO appears good. Currently, the use of BPs is recommended at the earliest by all major scientific societies in postmenopausal women and men ≥50 years at high risk of fracture receiving glucocorticoid therapy. BPs are the most commonly used anti-osteoporotic agents and they remain the current standard of care for GIO.


    • 1 December 2014
      • Vol. 33  (1) , 77-83

    In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density.

    by Maurizio Rossini, Ombretta Viapiana, Silvano Adami, Elena Fracassi, Luca Idolazzi, Carmela Dartizio, Maria Rosaria Povino, Giovanni Orsolini, Davide Gatti

    The objective of this study is to compare the serum levels of Dickkopf-1 (DKK1), a natural inhibitor of Wnt signalling, with parathyroid hormone (PTH) and bone involvement in patients with rheumatoid arthritis (RA). This cross-sectional study includes 154 postmenopausal women with RA and 125 healthy controls. DKK1, 25OH vitamin D (25OHD), bone turnover markers, and PTH serum levels were measured by ELISA; lumbar spine and hip bone mineral density (BMD) and the erosion score were obtained. The RA patients and healthy controls were not significantly different in terms of age, body mass index, and 25OHD serum levels. The mean level of DKK1 and PTH were significantly higher in patients with RA than in healthy controls (172±68 [SD] vs. 96±55 pmoL/L, and 30±15 vs 22±11, respectively; p<0.0001). DKK1 serum levels were positively correlated with age (p<0.05) only in the healthy controls, while they were correlated with PTH serum levels only in the RA patients (p<0.0001). Among the RA patients, DKK1 levels adjusted for age, PTH and disease duration were significantly higher in patients with bone erosions (176 vs. 167 pmoL/L, respectively; p<0.05). DKK1 levels adjusted for age and PTH were negatively correlated with total hip BMD (p<0.05). In the RA patients not on treatment with bisphosphonates, DKK1 serum levels positively correlated with C-terminal telopeptides of type I collagene serum levels (p<0.05). In patients with RA, serum levels of DKK1 are significantly increased, correlate with PTH and are associated with increased risk of bone erosions and osteoporosis. However, this finding deserves confirmation in a larger and more selected population.


  • Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis

    by Davide Gatti, Ombretta Viapiana, Luca Idolazzi, Elena Fracassi, Claudio Ionescu, Carmela Dartizio, Sonila Troplini, Vidya Kunnathully, Silvano Adami, Maurizio Rossini


  • Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial

    by Maurizio Rossini, Silvano Adami, Elena Fracassi, Ombretta Viapiana, Giovanni Orsolini, Maria Rosaria Povino, Luca Idolazzi, Davide Gatti

    Aim of this study was to evaluate the efficacy and tolerability of intra-articular (IA) clodronate, compared to saline solution, in patients with symptomatic knee osteoarthritis (KOA). In this double-blind phase 3 randomized clinical trial, patients were randomized to receive once weekly IA injection of 2 mg clodronate or placebo for 4 weeks with 12 weeks of follow-up. The primary objective was the sum of spontaneous, on passive movement, and at digital pressing pain relief assessed by visual analogue score (VAS) of 0–100 at 5 weeks after the final injection. Improving in Western Ontario MacMaster (WOMAC) scale, Lequesne index, consumption of acetaminophen, and physician or patient overall judgment were secondary objectives. Study population included 80 patients, 67 women and 13 men aged 66 ± 6 (SD) years. A significant improvement for all efficacy parameters was observed at all-time points in both groups. A significant difference in favor to clodronate in VAS for pain was observed 5 weeks after the last injection (−114.6 vs. −87.2 for clodronate and placebo group, respectively; p < 0.05). The improvements in Lequesne index, global KOA evaluation from both patients and investigators, and the WOMAC pain subscale were significantly greater in the clodronate group. The proportion of patients that did not require acetaminophen was significantly greater in the clodronate group (about 10 vs. 30 % for clodronate and placebo group, respectively; p < 0.05). IA 2 mg clodronate is associated with small and transient symptomatic and functional benefits and it is safe in KOA patients.


    • 24 June 2014
      • Vol. 32  (4) , 451-4

    Bisphosphonates in Complex Regional Pain syndrome type I: how do they work?

    by Massimo Varenna, Silvano Adami, Luigi Sinigaglia

    Complex Regional Pain syndrome type I (CRPS-I) is a disease characterised by extreme pain for which no gold-standard treatment exists to date. In recent years a possible role for bisphosphonates in the treatment of CRPS-I has been proposed. These drugs were first used for their effect in decreasing pain in bone diseases in which bisphosphonates act through their antiosteoclastic properties (metastatic disease, Paget disease, myeloma). In CRPS-I, enhanced osteoclastic activity has never clearly been demonstrated and the benefit shown is possibly exerted by different mechanisms of action. In this paper we review other conjectural mechanisms involved in reducing pain intensity and improving clinical signs and functional status in these patients. The results of most studies on this topic show that bisphosphonates may be effective in the early phases of the disease, when scintigraphic bone scan more frequently shows a local radiotracer accumulation that possibly means a high local concentration of the drug. These features probably represent the required conditions by which bisphosphonates might modulate various inflammatory mediators that are upregulated in CRPS-I. Patients in whom a scintiscan is often negative (long-standing disease or a primarily cold disease) could be less responsive to this treatment. With these limitations, bisphosphonates appear to present a therapeutic strategy that has been proven to reliably offer benefits in patients with CRPS-I.


  • Prevalence and incidence of rheumatoid arthritis in Italy

    by Maurizio Rossini, Elisa Rossi, Davide Bernardi, Ombretta Viapiana, Davide Gatti, Luca Idolazzi, Cristian Caimmi, Marisa DeRosa, Silvano Adami

    Aim of the study was to estimate the prevalence and incidence of rheumatoid arthritis (RA) from an administrative cohort consisting of 2,268,514 males and 2,446,769 females, aged ≥ 18 years, from 32 Italian Health Districts. The diagnosis of RA was certified by a qualified specialist and confirmed by ≥3 prescriptions of “specific drugs” (corticosteroids, DMARDs or “biological” agents) during 2011. Patients on “specific drugs” qualified as “active RA”; those who never had more than 4 prescriptions in the past were classified as “unlikely RA,” and those previously on chronic treatment but who discontinued therapy for >1 year were classified as “remission RA.” The patients with a diagnosis of RA were 22,801 (0.48 %) with a prevalence of “active RA,” “remission RA” and “confirmed RA” (Active + Remission RA) of 0.32, 0.09 and 0.41 % (95 % CI 0.38–0.44), respectively. The classification criteria tested in a fifth of the study population by direct analysis yielded >90 % accuracy and precision. The yearly incidence of “active RA” per 100,000 subjects was 48 (95 % CI 40–57) and 20 (95 % CI 10–30) for women and men, respectively. The peak for both prevalence and incidence was around the eighth decade of life. The female/male ratios for both prevalence and incidence were ca. 2.6 before the fifth decade of life, but approached unity in the ninth decade of life. The overall prevalence and incidence of RA in a large sample of the Italian population is only marginally lower than that reported from a similar administrative database of Sweden. With advancing age, the female/male ratio declines to about one.


  • High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register

    by On Behalf Of Gisea (Gruppo Italiano Studio Early Arthritis), Florenzo Iannone, Elisa Gremese, Gaia Gallo, Piercarlo Sarzi-Puttini, Costantino Botsios, Francesco Trotta, Stefania Gasperini, Mauro Galeazzi, Silvano Adami, et al.

    The aim of this study was to evaluate the clinical outcomes of etanercept in rheumatoid arthritis (RA) patients with moderate or severe disease activity. We analyzed data from the Italian biologics register Gruppo Italiano Studio Early Arthritides (GISEA) to investigate the rate of disease remission and functional improvement, based on the 28-Joint Disease Activity Score (DAS28) and the (Health Assessment Questionnaire (HAQ) score in RA patients with moderate or severe disease activity beginning etanercept therapy. Disease was defined as severe (H-RA) with DAS28 ≥5.1 and moderate (M-RA) with DAS28 ≥3.2 to 5.1 at baseline. Patients were considered in remission if DAS28 was ≤2.6, and HAQ ≤0.5 defined normal function. We enrolled 953 RA patients, 320 with M-RA and 633 H-RA. Age and disease duration were similar in the two cohorts, but H-RA patients had significantly more comorbidities (p < 0.01) and took significantly more disease-modifying antirheumatic drugs (p < 0.001) than M-RA patients. After 1 year, the percentage of patients achieving disease remission and normal function (DAS28 ≤2.6 plus HAQ ≤0.5) was higher in M-RA (21.4 %) than in H-RA patients (14.8 %, p = 0.007), regardless of the disease duration. Additionally, female gender (p = 0.006) and H-RA class (p = 0.002) negatively predicted disease remission at 1 year. However, the drug survival rate did not differ between the two subsets. This study confirms that etanercept was effective in the treatment of active RA, but best response, in terms of disease remission and normal function ability, was greater and easier to attain in M-RA patients. These findings may aid clinicians to choose the best strategy to treat RA.